
Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) – Analysts at HC Wainwright upped their Q1 2027 earnings estimates for shares of Inhibikase Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01.
IKT has been the subject of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Chardan Capital reissued a “neutral” rating and issued a $1.50 price objective on shares of Inhibikase Therapeutics in a research report on Thursday, November 12th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.75.
View Our Latest Analysis on IKT
Inhibikase Therapeutics Stock Down 4.6%
NASDAQ IKT opened at $1.45 on Monday. The firm’s fifty day simple moving average is $1.87 and its two-hundred day simple moving average is $1.93. Inhibikase Therapeutics has a 12-month low of $1.40 and a 12-month high of $2.61.
Hedge Funds Weigh In On Inhibikase Therapeutics
Several hedge funds have recently modified their holdings of IKT. Abel Hall LLC boosted its stake in Inhibikase Therapeutics by 15.0% in the 3rd quarter. Abel Hall LLC now owns 53,311 shares of the company’s stock worth $110,000 after purchasing an additional 6,959 shares in the last quarter. Spark Investment Management LLC purchased a new stake in Inhibikase Therapeutics during the 2nd quarter worth approximately $31,000. Renaissance Technologies LLC purchased a new stake in Inhibikase Therapeutics during the 1st quarter worth approximately $28,000. Seven Fleet Capital Management LP increased its stake in Inhibikase Therapeutics by 6.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company’s stock valued at $704,000 after purchasing an additional 21,300 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Inhibikase Therapeutics during the 1st quarter valued at approximately $48,000. Institutional investors and hedge funds own 3.81% of the company’s stock.
Inhibikase Therapeutics Company Profile
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Recommended Stories
- Five stocks we like better than Inhibikase Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
